BACKGROUND: Galantamine is a drug used for the treatment of Alzheimer's disease and some other cognitive disorders. It is an inhibitor of acetylcholinesterase; however, interaction with nicotinic acetylcholine receptors has also been reported. Owing to the significant role of cholinergic anti-inflammatory pathways in neuro-immunomodulation, we decided to examine the effect of galantamine on tularemia-infected BALB/c mice. METHODS: Animals were infected with Francisella tularensis LVS and treated with galantamine (0.1 mg/kg of body weight). Total mortality over the course of tularemia infection was assessed and interleukin 6 (IL-6) and interferon gamma (IFN-gamma) in plasma samples were measured by enzyme-linked immunosorbent assays. Apart from the cytokine assays, biochemical markers such as inorganic phosphate, uric acid, lactate dehydrogenase, gamma glutamyltransferase, creatinine phosphokinase and amylase were assayed. RESULTS: The modulation of immunity by galantamine depended on two opposing processes: up-regulation of IFN-gamma and down-regulation of IL-6. Tularemia infection resulted in significant nephropathy, as hyperphosphataemia and hyperuricaemia occurred in infected animals. In addition, galantamine resulted in the mitigation of nephropathy, and markers of kidney dysfunction were modulated. Alterations in mortality were also found in this study. CONCLUSIONS: Galantamine can significantly influence the immune response via the cholinergic anti-inflammatory pathway. Despite the decrease in IL-6 levels, galantamine treatment enhanced protection against the intracellular pathogen F. tularensis, resulting in the remission of some pathology and reduced mortality.

Centre of Biological Defence 56166 Techonin Czech Republic

Faculty of Veterinary Hygiene and Ecology University of Veterinary and Pharmaceutical Sciences Brno Palackeho 1 3 612 42 Brno Czech Republic

University of Defence Trebesska Hradec Kralove Czech Republic

Zobrazit více v PubMed

Mashkovsky MD, Kruglikova-Lvova RP. On the pharmacology of the new alkaloid galantamine. Farmakologia Toxicologia (Moscow) 1951;14:27–30.

Bartolucci C, Perola E, Pilger C, Fels G, Lamba D. Three dimensional structure of a complex of galanthamine (Nivalin) with acetylcholinesterase from Torpedo californica: implications for the design of new anti-Alzheimer drugs. Proteins. 2001 Feb;42(2):182–91. PubMed

Schilstrom B, Ivanov VB, Wiker C, Svensson TH. Galantamine enhances dopaminergic neurotransmission in vivo via allosteric potentiation of nicotinic acetylcholine receptors. Neuropsychopharmacology. 2007 Jan;32(1):43–53. PubMed

Senanarogn V, Poungvarin N, Phanthumchinda K, Thavichachart N, Chankrachang S, Praditsuwan R, et al. Safety and tolerability of galantamine in possible Alzheimer’s disease with or without cerebrovascular dementia in Thai patients. J Med Assoc Thai. 2009 Mar;92(Suppl 2):S12–S8. PubMed

Pohanka M. Alzheimer’s disease and related neurodegenerative disorders: implication and counteracting of melatonin. J Appl Biomed. 2011 Oct;9(4):185–96.

Pohanka M. Acetylcholinesterase inhibitors; a patent review (2008 – present) Expert Opin Ther Patents. doi: 10.1517/13543776.2012.701620. PubMed

Liu ZH, Ma YF, Wu JS, Gan JX, Xu SW, Jiang GY. Effect of cholinesterase inhibitor galanthamine on circulating tumor necrosis factor alpha in rats with lipopolysaccharide-induced peritonitis. Chin Med J (Engl) 2010 Jul;123(13):1727–30. PubMed

Edwards JA, Rockx-Brouwer D, Nair V, Celli J. Restricted cytosolic growth of Francisella tularensis subsp tularensis by IFN-gamma activation of macrophages. Microbiology. 2010 Feb;156(Pt 2):327–39. PubMed PMC

Cowley SG, Goldberg MF, Elkins KL. The membrane form of tumor necrosis factor is sufficient to mediate partial innate immunity to Francisella tularensis live vaccine strain. J Infect Dis. 2008 Jul;198(2):284–92. PubMed

Piotrovsky V, Van PeerA, Van OsselaerN, Armstrong M, Aerssens J. Galantamine population pharmacokinetics in patients with Alzheimer’s disease: modeling and simulations. J Clin Pharmacol. 2003 May;43(5):514–23. PubMed

Broad LM, Zwart R, Pearson KH, Lee M, Wallace L, McPhie GI, et al. Identification and pharmacological profile of a new class of selective nicotinic acetylcholine receptor potentiators. J Pharmacol Exp Ther. 2006 Sep;318(3):1108–17. PubMed

Jones CK, Byun N, Bubser M. Muscarinic and nicotinic acetylcholine receptor agonists and allosteric modulators for the treatment of schizophrenia. Neuropsychopharmacology. 2012 Jan;37(1):16–42. PubMed PMC

Takata K, Kitamura Y, Saeki M, Terada M, Kagitani S, Kitamura R, et al. Galantamine-induced amyloid-beta clearance mediated via stimulation of microglial nicotinic acetylcholine receptors. J Biol Chem. 2010 Dec;285(51):40180–91. PubMed PMC

Oke SL, Tracey KJ. The inflammatory reflex and the role of complementary and alternative medical therapies. Ann NY Acad Sci. 2009 Aug;1172(1):172–80. PubMed PMC

Pavlov VA, Parrish WR, Rosas-Ballina M, Ochani M, Puerta M, Ochani K, et al. Brain acetylcholinesterase activity controls systemic cytokine levels through the cholinergic anti-inflammatory pathway. Brain Behav Immun. 2009 Jan;23(1):41–5. PubMed PMC

Satapathy SK, Ochrani M, Dancho M, Hudson LK, Rosas-Ballina M, Valdes-Ferrer SI, et al. Galantamine alleviates inflammation and other obesity-associated complications in high-fat diet-fed mice. Mol Med. 2011 Jul;17(7-8):599–606. PubMed PMC

Edwards JA, Rockx-Brouwer D, Nair V, Celli J. Restricted cytosolic growth of Francisella tularensis subsp. tularensis by IFN-gamma activation of macrophages. Microbiology. 2010 Feb;156(Pt 2):327–39. PubMed PMC

Bandouchova H, Pohanka M, Vlckova K, Damkova V, Peckova L, Sedlackova J, et al. Biochemical responses and oxidative stress in Francisella tularensis infection: a European brown hair model. Acta Vet Scand. 2011 Jan;13:53–2. PubMed PMC

Tilley WS, Garman RW, Stone WJ. Tularemia complicated by acute renal failure. South Med J. 1983 Feb;76(2):273–4. PubMed

Onuigbo M, Hise M, Ramos E, Traong N, Amelung P, Drachenberg C. Fatal granulomatous broncho-pneumonia complicated by acute renal failure. South Med J. 2002 Aug;95(8):947–9. PubMed

Wang DW, Zhou RB, Yao YM. Role of cholinergic anti-inflammatory pathway in regulating host response and its interventional strategy for inflammatory diseases. Chin J Traumatol. 2009 Dec;12(6):355–64. PubMed

Pohanka M, Pavlis O, Pikula J, Treml F, Kuca K. Modulation of tularemia disease progress by the bisquaternary pyridinium oxime HI-6. Acta Vet Brno. 2010 Nov;79(3):443–8.

Bandouchova H, Sedlackova J, Pohanka M, Novotny L, Hubalek M, Treml F, et al. Tularemia induces different biochemical responses in BALB/c mice and common voles. BMC Infect Dis. 2009 Jun;26(9):101. PubMed PMC

Pohanka M. Alpha7 nicotinic acetylcholine receptor is a target in pharmacology and toxicology. Int J Mol Sci. 2012 Feb;13(2):2219–38. Epub 2012 Feb 17. PubMed PMC

Giunta B, Ehrhart J, Townsend K, Sun N, Vendrame M, Shytle D, et al. Galantamine and nicotine have a synergistic effect on inhibition of microglial activation induced by HIV-1 gp120. Brain Res Bull. 2004 Aug;64(2):165–70. PubMed